Gefitinib

被引:58
作者
Culy, CR [1 ]
Faulds, D [1 ]
机构
[1] Adis Int Ltd, Auckland 10, New Zealand
关键词
D O I
10.2165/00003495-200262150-00008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gefitinib (ZD1839) is an orally active selective inhibitor of epidermal growth factor receptor tyrosine kinase, an enzyme that regulates intracellular signalling pathways implicated in the proliferation and survival of cancer cells. In human non-small cell lung cancer (NSCLC) cell lines and xenografts, gefitinib dose-dependently inhibited cellular proliferation and tumour growth, and potentiated the cytotoxic effects of chemotherapy and/or radiation. Gefitinib is orally bioavailable and is cleared via the cytochrome P450 3A4 pathway. In patients receiving gefitinib (50 to 700 mg/day) in phase I trials, steady-state plasma concentration was reached in 7 to 10 days. In patients with advanced NSCLC who had failed one or two prior chemotherapies, gefitinib 250 or 500mg once daily induced an objective response in approximate to 19% of patients in a double-blind trial (n = 210). In another double-blind trial including 216 patients with NSCLC who had failed two or more prior chemotherapies, gefitinib 250 or 500mg once daily induced an objective response in 11.8 and 8.8% of patients, respectively; approximate to40% showed an improvement in disease-related symptoms. Gefitinib was generally well tolerated and the most common adverse events were mild skin rashes and diarrhoea.
引用
收藏
页码:2237 / 2248
页数:12
相关论文
共 46 条
[1]  
Albanell J, 2001, CANCER RES, V61, P6500
[2]   Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 [J].
Albanell, J ;
Rojo, F ;
Baselga, J .
SEMINARS IN ONCOLOGY, 2001, 28 (05) :56-66
[3]   Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].
Albanell, J ;
Rojo, F ;
Averbuch, S ;
Feyereislova, A ;
Mascaro, JM ;
Herbst, R ;
LoRusso, P ;
Rischin, D ;
Sauleda, S ;
Gee, J ;
Nicholson, RI ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :110-124
[4]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[5]   Tyrosine kinase inhibitors-ZD1839 (Iressa) [J].
Arteaga, CL ;
Johnson, DH .
CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) :491-498
[6]  
*ASTR, 2002, IR GEF 1 APPR WORLD
[7]  
*ASTR, 2002, SINGL DOS OR PHARM Z
[8]  
*ASTR, 2002, IR TABL 250 ANT DRUG
[9]   Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].
Barker, AJ ;
Gibson, KH ;
Grundy, W ;
Godfrey, AA ;
Barlow, JJ ;
Healy, MP ;
Woodburn, JR ;
Ashton, SE ;
Curry, BJ ;
Scarlett, L ;
Henthorn, L ;
Richards, L .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914
[10]   ZD1839 ('Iressa')1,2 as an anticancer agent [J].
Baselga, J ;
Averbuch, SD .
DRUGS, 2000, 60 (Suppl 1) :33-40